Biovail News

Toronto - The Canadian Press Published on Thursday, Nov. 05, 2009 12:48PM EST B iovail Corp.'s BVF-T profit fell to $40.4-million in the third quarter, as the impact of special items offset a 17.3-per-cent increase in revenue generated by the Canadian pharmaceutical company's products.

Biovail Corp. said Thursday that one-time costs hurt earnings in the third quarter.

Biovail Corporation today announced financial results for the three-month and nine-month periods ended September 30, 2009.

Biovail has been making pills in Steinbach for more than 10 years now, but judging by the proliferation of mobile sign-boards advertising positions needing to be filled at its plant, you might think they were staffing up a brand-new operation.

BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical Trials and upcoming FDA approvals & decisions.

It's easy to become discouraged from trading, with the numerous distractions we face daily, and the setbacks that tamper with the domestic market.

Drug stocks advanced Tuesday while shares of Mannkind Corp. tanked after it revealed in a regulatory filing that it does not foresee entering into a marketing partnership for its inhaled insulin product before the end of the year.

Posted October 6, 2009, 10:26 a.m. Stock of San Diego biotech Acadia Pharmaceuticals has zoomed 19.39% this morning to $1.97. My advice: stay clear of this one.

Biovail Corporation today provided an update on its Phase III program with pimavanserin for Parkinsona s disease psychosis , which is being pursued in collaboration with ACADIA Pharmaceuticals Inc.

On this day, we have begun tracking the following companies as they have shown remarkable correction in recent days, you can access these free reports with a number of other reviews by signing up for your complimentary membership at : http://www.rothmanresearch.com/ Companies been researched today are: XTO Energy Inc.

Xerox says it will buy Affiliated Computer Services in a cash-and-stock deal valued at $5.75 billion.

Shares of Canadian drug developer Biovail Corp. rose Friday after a J.P. Morgan analyst started coverage on the stock with an "Overweight" rating and $19 price target.

U.S. stock market futures turned lower after disappointing durable goods order data Friday.

Ilhavo, Portugal a ' 22/09/2009 a ' SADIF Investment Analytics, announces a new summary due diligence report covering Biovail Corporation .

The news that Biovail will pay $25 million in fines for bribing doctors into prescribing the blood pressure drug Cardizem turns out to be just the tip of the iceberg.

Shares of Miami-based Noven Pharmaceuticals gained ground Tuesday after a Jefferies & Co.

A New Jersey pharmaceuticals firm will pay nearly $25 million in criminal and civil fines after pleading guilty to federal charges that it made illegal payments to encourage doctors to prescribe a blood pressure drug.

Shares of Synchronoss Technologies Inc. got a boost Thursday after a Thomas Weisel Partners analyst upgraded the company, calling it "undervalued and overlooked" by investors.

Last year, we posted about the guilty plea by the US arm of the Canadian firm Biovail to charges that it paid physicians kickbacks to prescribe a long-acting version of the drug diltiazam.

Acting United States Attorney Michael K. Loucks, Warren T. Bamford, Special Agent in Charge of the Federal Bureau of Investigation - Boston Field Division; Susan J. Waddell, Special Agent in Charge of the Department of Health and Human Services - Office of Inspector General announced today that BIOVAIL PHARMACEUTICALS, LLC., a corporation with ...